Product Description
SYN-045 is a highly selective PGI2 receptor agonist. Currently, in preclinical studies, SYN-045 shows high targeting selectivity, has obvious anti-pulmonary hypertension effects in animals, and its toxicity is low, which is conducive to long-term oral administration. (Sourced from: https://www.webull.com/news/10129086276207616)
Mechanisms of Action: PGI2 Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Shijiazhuang No.4 Pharmaceutical Co., Ltd.
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for SYN-045](https://pryzm-maps.s3.us-west-2.amazonaws.com/666666current_maps.png)
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Hypertension, Pulmonary
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
ChiCTR2400083835 | N/A |
Recruiting |
Healthy Volunteers |
2024-12-31 |
|
CTR20241522 | P1 |
Unknown |
Hypertension, Pulmonary |
None |